DAFTAR PUSTAKA

1. McGlynn KA, London WT. The Global Epidemiology of Hepatocellular Carcinoma: Present and Future. Clin Liver Dis. 2011;15(2):223–43.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Liu Y, Liu L. Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. Cancers (Basel). 2022;14(18).
4. Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: A case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22(7):1104–11.
5. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: Implications on prognosis and management. ESMO Open. 2016;1(2):1–16.
6. Alsudaney M, Ayoub W, Kosari K, Koltsova E, Mohammed N, Adetyan H, et al. Pathophysiology of liver cirrhosis and risk correlation between immune status and the pathogenesis of hepatocellular carcinoma. Hepatoma Res. 2025;11(7).
7. Jiang W, Wu T, Shi X, Xu J. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma. *Bioengineered*. 2021;12(1):7941-7949. doi:10.1080/21655979.2021.1982844
8. Krings G, Ramachandran R, Jain D, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. *Mod Pathol*. 2013;26(6):782-791. doi:10.1038/modpathol.2012.243
9. Toberson MS NIPYRMSM. Hepatocellular Carcinoma. In: Digestive System Tumours; WHO classification. 5th ed. Lyon, France: IARC Library Cataloguing in Publication Data;2019.
10. Sweed D, Sweed E, Moaz I, Mosbeh A, Fayed Y, Elhamed SMA, et al. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. World J Surg Oncol [Internet]. 2022;20(1):1–20. Available from: https://doi.org/10.1186/s12957-022-02764-2.
11. Fowler KJ, Burgoyne A, Fraum TJ, Hosseini M, Ichikawa S, Kim S et al. Patgologic, molecular, and prognostic radiologic features of hepatocellular carcinoma Radiographics. 2021; 41(6): 1611-31.
12. Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, Aishima S, Taketomi A, Shirabe K, Ishida T, Maehara Y. Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol 2012; 19: 2027-2034 [PMID: 22203184 DOI: 10.1245/ s10434-011-2195-0]

hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013; 20: 325-339 [PMID: 23149850 DOI: 10.1245/ s10434-012-2513-

1]

13. Hasan I. Profil klinis dan kesintaan pasien karsinoma sel hati di Rumah Sakit Rujukan Tersier Indonesia Tahun 2015-2021. Jurnal Penyakit Dalam Indonesia. 2023 Jun 30;10(2).
14. Huang R, Mo D, Wu J, Ai H, Lu Y. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. Medicine. 2018: 1-9.
15. Ren F, Sheng WQ, Du X. CD133: A cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 2013: 2603-11.
16. Zhou Y, Xia L, Wang H, Oyang L, Su M, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018: 33403-15.
17. Moharil R, Dive A, Khandekar S, Bodhade A. Cancer stem cells: An insight. J Oral Maxillofac Pathol. 2017.
18. Kimura O, Kondo Y, Kogure T, et al. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int. 2014;2014.
19. Yamashita T, Ji J, Budhu A, et al. EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology. 2009;136(3).
20. Kabakov A, Yakimova A, Matchuk O. Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy. Cells. 2020
21. Quiroz Reyes AG, Lozano Sepulveda SA, Martinez-Acuña N, et al. Cancer Stem Cell and Hepatic Stellate Cells in Hepatocellular Carcinoma. Technol Cancer Res Treat. 2023;22.
22. Thakolwiboon S. Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis. J Proteomics Bioinform. 2014;07(10).
23. Do HQ, Luong AB, Bonazza D, et al. Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma. Ann Hepatol. 2020;19(6):645-652.
24. Sekar V, Veerabathiran R, Pandian A, Sivamani G. Targeting liver cancer stem cell through EpCAM therapy targeted with chemotherapy endorse enhanced progression in hepatocellular carcinoma. Egypt Liver J. 2023;13(1).
25. Koh HM, Lee HJ, Kim DC. Prognostic and clinicopathological value of CD90 expression in cancer patients: A systematic review and meta-analysis. Transl Cancer Res. 2021;10(7):3356–63.
26. Dai XM, Huang T, Yang SL, Zheng XM, Chen GG, Zhang T. Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma. Dis Markers. 2017;2017.
27. Zhao RC, Zhou J, Chen KF, et al. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection. Neoplasma. 2016;63(2):288-298.
28. Zhou L, Zhu Y. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. Int J Surg. 2018;56:274-280.
29. Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin

Liver Dis [Internet]. 2023;27(1):85–102. Available from: https://doi.org/10.1016/j.cld.2022.08.004

30. Bartolini I, Nelli T, Russolillo N, Cucchetti A, Pesi B, Moraldi L, et al. Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study. Am J Surg [Internet]. 2021;222(3):599–605. Available from: https://doi.org/10.1016/j.amjsurg.2021.01.023
31. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and managemen. Gastroenterol Hepatol. 2019;16(10):589–604.
32. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89.
33. Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma. 2021;Volume 8:1415-1444. doi:10.2147/jhc.s336858
34. Zhao Z, Cui T, Wei F, et al. Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target. Front Oncol. 2024;14. doi:10.3389/fonc.2024.1367364
35. Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1). doi:10.1038/s41392-021-00762-6
36. Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020;12(2). doi:10.3390/cancers12020491
37. Vasuri F, Visani M, Acquaviva G, et al. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. World J Gastroenterol. 2018;24(25):2647-2660. doi:10.3748/wjg.v24.i25.2647
38. Jeng KS, Chang CF, Sheen IS, Jeng CJ, Wang CH. Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. Int J Mol Sci. 2023;24(2). doi:10.3390/ijms24021417
39. Guo Y, Wu G, Yi J, et al. Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway. Front Oncol. 2022;11. doi:10.3389/fonc.2021.763539
40. Gungor MZ, Uysal M, Senturk S. The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers (Basel). 2022;14(4). doi:10.3390/cancers14040940
41. Ahluwalia S. Identification Of Novel Viral-Host Interactions In Hepatitis B Virus Replication And Pathogenesis Of Hepatitis B Virus- Related Hepatocellular Carcinoma. Published online 2022.
42. Loy LM, Low HM, Choi JY, Rhee H, Wong CF, Tan CH. Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review. Am J Roentgenol. 2022;219(2):212–23.
43. Chelliah AR, Radhi JM. Hepatocellular Carcinoma with Prominent Intracytoplasmic Inclusions: A Report of Two Cases. Case Reports Hepatol.

2016;2016:1-3. doi:10.1155/2016/2032714

44. Mitchell CM, Sturgis CD. Lipid-rich hepatocellular carcinoma in fine-needle aspiration biopsy. Diagn Cytopathol. 2009;37(1):36-37. doi:10.1002/dc.20891
45. Viki M, Morrow R. Metastatic Hepatocellular Carcinoma Represents an Important but Rare Pitfall in the Diagnostic Evaluation of ER Negative Ovarian Malignancy: A Case Report. Int J Gynecol Pathol. 2024;43(4):378-381. doi:10.1097/PGP.0000000000000995
46. Sempoux C, Paradis V, Saxena R. Variant differentiation patterns in primary liver carcinoma. Semin Diagn Pathol. 2017;34(2):176-182. doi:10.1053/j.semdp.2017.02.001
47. Jargalsaikhan O. Histopathological features of hepatocellular carcinoma in patients with hepatitis B and hepatitis D viruses infection: A single-institution study from Mongolia. Published online 2024.
48. Murtha-Lemekhova A, Fuchs J, Schulz E, et al. Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. J Hepatocell Carcinoma. 2021;Volume 8:1269-1279. doi:10.2147/jhc.s328198
49. Roberts DE, Kakar S, Mehta N, Gill RM. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol. 2018;42(7):855-865. doi:10.1097/PAS.0000000000001053
50. N. Martins-Filho S, Alves V. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surg Exp Pathol. 2019;2:23. doi:10.1186/s42047-019-0047-6
51. Gisder DM, Tannapfel A, Tischoff I. Histopathology of hepatocellular carcinoma-when and what. Hepatoma Res. 2022;8.
52. Torbenson MS. Morphologic Subtypes of Hepatocellular Carcinoma. Gastroenterol Clin North Am [Internet]. 2017;46(2):365–91. Available from: http://dx.doi.org/10.1016/j.gtc.2017.01.009
53. López CL, Calvo M, Cámara JC, García-Paredes B, Gómez-Martin C, López AM, et al. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clin Transl Oncol [Internet]. 2024;26(11):2800–11. Available from: https://doi.org/10.1007/s12094-024-03568-4
54. Kim JM, Hyun MH, Park JW, Kim BW, Oh D, Kwon CHD, et al. Tumor size predicts prognosis of hepatocellular carcinoma independent of Barcelona Clinic Liver Cancer stage. *World J Gastroenterol*. 2021;27(15):1765–78. doi:10.3748/wjg.v27.i15.1765.
55. Sakamoto K, Ogawa K, Tamura K, Honjo M, Funamizu N, Takada Y. Prognostic Role of the Intrahepatic Lymphatic System in Liver Cancer. Cancers (Basel). 2023;15(7):1–16.
56. HSIEH C-H, WEI C-K, YIN W-Y, CHANG C-M, TSAI S-J, WANG L-Y, et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol Clin Oncol. 2015;3(1):252–6.
57. Zhang L, Lin J bin, Jia M, Zhang C cai, Xu R, Guo L, et al. Clinical and imaging features preoperative evaluation of histological grade and microvascular infiltration of hepatocellular carcinoma. BMC Gastroenterol [Internet]. 2022;22(1):1–9. Available from: https://doi.org/10.1186/s12876-022-02449-w

58. Yadav AK, Desai NS. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects. Stem Cell Rev Rep. 2019: 331 55.
59. Jiao X, Qian X, Wu L, Li B, Wang Y, Kong X, Xiong L. microRNA: The Impact on Cancer Stemness and Therapeutic Resistance. Cells. 2019.
60. Yang L, Shi P, Zhao G, Xu J, Peng W, Zet al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020.
61. Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumour Biol. 2017.
62. Li R, Dong H, Zhu J, Yi H, Liu S. Overexpression of CD133 confers poor prognosis in colorectal cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2019: 1492 502.
63. Fan G, Xie T, Li L, Tang L, Han X, Shi Y. Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. npj Precis Oncol. 2024;8(1).
64. Niu Q, Ye S, Zhao L, Qian Y, Liu F. The role of liver cancer stem cells in hepatocellular carcinoma metastasis. Cancer Biol Ther. 2024;25(1).
65. Liu Y, Yeh C-T, Lin K-H. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. MDPI. 2020;9:1331.
66. El-Kholy MA, Abu-Seadah SS, Hasan A, et al. The Role of Epithelial Cell Adhesion Molecule Cancer Stem Cell Marker in Evaluation of Hepatocellular Carcinoma. Med. 2024;60(6).
67. Krause J, von Felden J, Casar C, et al. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. BMC Cancer. 2020;20(1).
68. Pandit H, Li Y, Zheng Q, et al. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget. 2020;11(22):2047-2060.
69. Warneke VS, Behrens HM, Haag J, Krüger S, Simon E, Mathiak M, et al. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br J Cancer. 2013;109(8):2217–27.
70. Park DJ, Sung PS, Kim JH, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1).
71. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell. 2008;13(2):153-166.
72. Yamashita T, Honda M, Nakamoto Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57(4):1484-1497.
73. Asakura N, Nakamura N, Muroi A, et al. Expression of cancer stem cell markers epcam and cd90 is correlated with anti- and pro-oncogenic epha2 signaling in hepatocellular carcinoma. Int J Mol Sci. 2021;22(16).
74. Luong AB, Do HQ, Tarchi P, et al. The mrna distribution of cancer stem cell marker cd90/thy-1 is comparable in hepatocellular carcinoma of eastern and western populations. Cells. 2020;9(12).
75. Lee Y, Park H, Lee H, Cho JY, Yoon YS, Choi YR et al. The

clinicopathologycal and prognostic significance of the gross classification of hepatocellular carcinoma. J Pathol Transl Med. 2018 Mar 1; 52(2): 85-92.

76. Radu IP, Scheiner B, Schropp J, Delgado MG, Schwacha-Eipper B, Jin C, et al. The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2024;16(23).
77. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY, et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol [Internet]. 2024;22(2):305–14. Available from: https://doi.org/10.1016/j.cgh.2023.07.029.
78. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38–46.
79. Lang H, Sotiropoulos GC, Dömland M, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005;92:198–202.
80. Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? - No, please don't. J Hepatol. 2005;43(4):563–8.
81. Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018; 68: 103-112 [PMID: 29281854 DOI: 10.1002/hep.29762]
82. Vij M, Calderaro J. Pathologic and molecular feature of hepatocellular carcinoma: An Update. World J Hepatol. 2021; 13(4): 393-410.
83. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2018; 33: 347-354 [PMID: 28589639 DOI: 10.1111/jgh.13843]
84. Yamashita T, Forgues M, Wang W, Jin WK, Ye Q, Jia H, et al. EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68(5):1451–61.
85. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004;23(34):5748–58.
86. Wang MH, Sun R, Zhou XM, Zhang MY, Lu J Bin, Yang Y, et al. Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death Dis [Internet]. 2018;9(1). Available from: http://dx.doi.org/10.1038/s41419-017-0013-8
87. Zhang J, Qi YP, Ma N, Lu F, Gong WF, Chen B, et al. Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma. J Cancer. 2020;11(11):3400–6.
88. Mal A, Bukhari AB, Singh RK, Kapoor A, Barai A, Deshpande I, et al. EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer. Front Cell Dev Biol. 2021;8(January):1–16.

89. Park SY, Bae JS, Cha EJ, Chu HH, Sohn JS, Moon WS. Nuclear EpICD expression and its role in hepatocellular carcinoma. Oncol Rep. 2016;36(1):197–204.
90. Lima LDP, Machado CJ, Rodrigues JBSR, Vasconcellos LDS, Junior EP, Vidigal PVT, et al. Immunohistochemical coexpression of epithelial cell adhesion molecule and alpha-fetoprotein in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2018;2018:1–8.
91. Luo J, Wang P, Wang R, Wang J, Liu M, Xiong S, et al. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget. 2016;7(8):9525–37.
92. Sukowati CHC, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C. The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. PLoS One. 2013;8(10):1–11.
93. Kawakami Y, Okada H, Nio K, Hayashi T, Seki A, Nakagawa H, et al. Transcription factor JUNB is required for transformation of EpCAM-positive hepatocellular carcinoma (HCC) cells into CD90-positive HCC cells in vitro. Cell Death Dis [Internet]. 2025;16(1). Available from: http://dx.doi.org/10.1038/s41419-025-07602-3
94. Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang B De. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014;20(8):2098–106.
95. Ou, Zhengrong, Fu, Shuoshuo, Yi, Jian , Huang, Jingxuan and Zhu W. Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta-analysis. Spandidos Publ. 2024;28:536.
96. Zhang, Ketao , Che Siayo, Su Zheng, Zheng Shangyou, Zhang Huayao, Yang Shanglin, Li Wenda LJ. CD90 promotes cell migration, viability and sphere-forming ability of hepatocellular carcinoma cells. Int J Mol Med. 2018;41:946–854
97. Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer [Internet]. 2015;14(1):1–11. Available from: http://dx.doi.org/10.1186/s12943-015-0426-x
98. Liu H, Li B. The functional role of exosome in hepatocellular carcinoma. J Cancer Res Clin Oncol [Internet]. 2018;144(11):2085–95. Available from: http://dx.doi.org/10.1007/s00432-018-2712-7